Notch Signaling Mediates Astrocyte Abnormality in Spinal Muscular Atrophy Model Systems.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 03 2019
Historique:
received: 25 09 2018
accepted: 04 12 2018
entrez: 8 3 2019
pubmed: 8 3 2019
medline: 25 9 2020
Statut: epublish

Résumé

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by the degeneration of spinal motor neurons and muscle atrophy. The disease is mainly caused by low level of the survival motor neuron (SMN) protein, which is coded by two genes, namely SMN1 and SMN2, but leads to selective spinal motor neuron degeneration when SMN1 gene is deleted or mutated. Previous reports have shown that SMN-protein-deficient astrocytes are abnormally abundant in the spinal cords of SMA model mice. However, the mechanism of the SMN- deficient astrocyte abnormality remains unclear. The purpose of this study is to identify the cellular signaling pathways associated with the SMN-deficient astrocyte abnormality and propose a candidate therapy tool that modulates signaling. In the present study, we found that the astrocyte density was increased around the central canal of the spinal cord in a mouse SMA model and we identified the dysregulation of Notch signaling which is a known mechanism that regulates astrocyte differentiation and proliferation, in the spinal cord in both early and late stages of SMA pathogenesis. Moreover, pharmacological inhibition of Notch signaling improved the motor functional deficits in SMA model mice. These findings indicate that dysregulated Notch signaling may be an underlying cause of SMA pathology.

Identifiants

pubmed: 30842449
doi: 10.1038/s41598-019-39788-w
pii: 10.1038/s41598-019-39788-w
pmc: PMC6403369
doi:

Substances chimiques

Receptors, Notch 0
SMN2 protein, mouse 0
Smn1 protein, mouse 0
Survival of Motor Neuron 1 Protein 0
Survival of Motor Neuron 2 Protein 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3701

Références

J Neuropathol Exp Neurol. 2014 Jun;73(6):519-35
pubmed: 24806302
J Neurosci. 2012 Mar 14;32(11):3818-29
pubmed: 22423102
J Vis Exp. 2011 Oct 03;(56):
pubmed: 21988897
Stem Cells Transl Med. 2016 Feb;5(2):152-63
pubmed: 26683872
Neurobiol Dis. 2010 Mar;37(3):493-502
pubmed: 19833209
Int J Mol Sci. 2013 May 29;14(6):11424-37
pubmed: 23759991
Mol Cell Biol. 2007 Jun;27(11):3982-94
pubmed: 17371842
Genes Dev. 2012 May 1;26(9):891-907
pubmed: 22549954
J Clin Invest. 2011 Aug;121(8):3029-41
pubmed: 21785219
Cold Spring Harb Perspect Biol. 2014 Nov 07;7(2):a020420
pubmed: 25380660
J Anat. 2005 Sep;207(3):265-9
pubmed: 16185251
Cell Struct Funct. 2013;38(1):55-66
pubmed: 23439558
Nat Commun. 2015 Feb 05;6:6195
pubmed: 25652697
J Neurosci. 2012 Jun 20;32(25):8703-15
pubmed: 22723710
Nature. 1995 Jun 29;375(6534):761-6
pubmed: 7596407
Nat Cell Biol. 2004 Jun;6(6):547-54
pubmed: 15156153
J Clin Invest. 2007 Mar;117(3):659-71
pubmed: 17318264
Nat Neurosci. 2005 May;8(5):616-25
pubmed: 15852015
Hum Mol Genet. 2017 Sep 1;26(17):3409-3420
pubmed: 28637335
Genes Dev. 2003 Jul 1;17(13):1677-89
pubmed: 12842915
J Neurosci. 2016 Feb 24;36(8):2543-53
pubmed: 26911699
J Neurosci. 2017 May 24;37(21):5309-5318
pubmed: 28450545
Dev Cell. 2009 Feb;16(2):245-55
pubmed: 19217426
Lancet. 2017 Dec 17;388(10063):3017-3026
pubmed: 27939059
Neurotherapeutics. 2015 Apr;12(2):303-16
pubmed: 25631888
Eur J Pharmacol. 2017 Nov 5;814:161-168
pubmed: 28826912
Stem Cells. 2015 Feb;33(2):403-15
pubmed: 25335858
Glia. 2013 Sep;61(9):1418-1428
pubmed: 23839956
Neurobiol Dis. 2007 Aug;27(2):207-19
pubmed: 17561409
Hum Mol Genet. 1995 Oct;4(10):1927-33
pubmed: 8595417
Development. 2012 Jul;139(14):2477-87
pubmed: 22675209
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5153-62
pubmed: 27535937
J Neurochem. 2008 Dec;107(6):1471-81
pubmed: 19094054
J Exp Neurosci. 2015 Nov 04;9(Suppl 2):25-34
pubmed: 26568684
Hum Mol Genet. 2015 Jul 15;24(14):4094-102
pubmed: 25911676
Front Neuroanat. 2012 May 28;6:18
pubmed: 22654736
PLoS One. 2012;7(9):e46353
pubmed: 23029491
PLoS One. 2014 Sep 05;9(9):e106818
pubmed: 25191843
Neurobiol Dis. 1996 Apr;3(2):97-110
pubmed: 9173917
PLoS One. 2013 Sep 23;8(9):e75866
pubmed: 24086650
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6307-11
pubmed: 10339583
Neuron. 2011 Mar 10;69(5):840-55
pubmed: 21382546
Lancet. 2017 Dec 17;388(10063):2964-2965
pubmed: 27939062
Neural Regen Res. 2017 Feb;12(2):203-204
pubmed: 28400795
J Neuropathol Exp Neurol. 1998 Aug;57(8):738-45
pubmed: 9720489
Dis Model Mech. 2011 Jul;4(4):457-67
pubmed: 21708901
Hum Mol Genet. 2005 Mar 15;14(6):845-57
pubmed: 15703193

Auteurs

Kazuki Ohuchi (K)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Michinori Funato (M)

Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Yuta Yoshino (Y)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.

Shiori Ando (S)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Satoshi Inagaki (S)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Arisu Sato (A)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Chizuru Kawase (C)

Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Junko Seki (J)

Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Toshio Saito (T)

Department of Neurology, Toneyama National Hospital, Osaka, Japan.

Hisahide Nishio (H)

Department of Occupational Therapy, Faculty of Rehabilitation, Kobe Gakuin University, Kobe, Japan.

Shinsuke Nakamura (S)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.

Masamitsu Shimazawa (M)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.

Hideo Kaneko (H)

Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan.

Hideaki Hara (H)

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan. hidehara@gifu-pu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH